Market Overview - The market performance is generally poor before major holidays due to concerns about potential issues during the break, with the Hang Seng Index dropping by 1.72% [1] - The U.S. non-farm payroll data exceeded expectations, causing the probability of a Fed rate cut in March to plummet from 20% to 8%, which could negatively impact the stock market if the upcoming CPI data is also unfavorable [1] - The Nasdaq experienced a significant drop of over 2% due to AI-related fears, leading to a chain reaction where investors sold gold to cover margin calls, despite no fundamental deterioration in gold [1] AI and Technology Sector - The subscription service GLM Coding Plan by Zhihui (02513) announced a price increase due to strong market demand, with user growth and usage volume rapidly increasing [2] - Zhihui's GLM-5 model ranks first in three major agent evaluation benchmarks, and its coding capabilities are approaching those of Claude Opus 4.5, indicating a strong competitive position [2] - MiniMax+ (00100) also saw a rise of over 15%, both companies reaching historical highs, with expectations of foreign capital focusing on driving up stock prices after the Spring Festival [2] Automotive Industry - The Ministry of Industry and Information Technology is soliciting opinions on mandatory national standards for intelligent connected vehicles, which will replace the previous recommended standards [3] - The new standards will introduce safety guarantees and certification systems, establishing product access conditions and detailing technical indicators and simulation testing requirements [3] - Companies in the intelligent driving sector, such as Nari Technology (01316) and Zhejiang Shibao (01057), experienced stock price increases following the announcement [3] Robotics Sector - MicroPort Robotics-B (02252) reported that its core product, the Tumi laparoscopic surgical robot, has surpassed 200 global commercial orders, with successful surgeries conducted in nearly 10 countries [4] - The company has achieved a 100% success rate in nearly 800 remote surgeries, leading to a stock price increase of over 11% [4] - Other companies in the robotics field, such as Yujia Technology (02515) and UBTECH (09880), also saw stock price increases following MicroPort's announcement [4] Metals Sector - Reports indicate that Trump is considering reducing tariffs on aluminum products, which could provide opportunities for the aluminum sector during the adjustment period [5] - The aluminum sector experienced a notable drop, but the current aluminum premium in the U.S. indicates that tariff costs are primarily borne by American consumers rather than foreign producers [6] - Potential tariff reductions could positively impact U.S. aluminum demand, suggesting a neutral to slightly bullish outlook for the aluminum sector [6] Consumer Sector - China Duty Free Group (01880) reported strong sales data following the opening of Hainan's duty-free market, with sales reaching 1.106 billion yuan during the Spring Festival [7] - The company is set to implement zero-tariff policies for daily consumer goods and has planned multiple promotional activities to boost sales [7] - A significant acquisition of DFS in the Greater China region and strategic investment from LVMH is expected to enhance the company's market position and resource access [7]

机构：光大证券 研究员：吴佳青 事件：公司近期公告1）根据微创医疗集团会计政策其无法控制微创脑科学但仍对其保持重大影响力， 故终止合并微创脑科学，构成须予披露交易。2）微创心通召开股东大会，审议通过并购微创心律管理 有限公司的重大资产重组议案。此次并购将推动微创医疗旗下结构性心脏病与心律管理两大核心业务板 块的深度整合。 点评： 盈利预测与评级：综合考虑集采影响、公司降低各项费用、聚焦核心业务等因素，我们预计公司有望实 现持续减亏，我们上调25~26 年净利润预测为-30/96 百万美元（原值为-59/91 百万美元），新增27 年净 利润预测为133 百万美元。公司为国内高值耗材领军企业，研发实力强劲，维持"买入"评级。 风险提示。高值耗材降价超预期、骨科减亏低于预期、收购整合风险等。 治理结构改善注入新动能，出海业务成为核心增长引擎。公司治理层面，上实资本旗下基金成为公司重 要战略股东，有望在治理和业务发展方面注入新动能。公司近期完成心律管理与结构性心脏病业务的重 组，旨在打造综合心脏病平台，新公司将融合微创心律管理的AI 诊断及算法技术，与微创心通在结构 性心脏病介入治疗、输送系统及生物材料方面的技术积 ...

Core Viewpoint - The report from Everbright Securities indicates that MicroPort Medical (00853) is expected to achieve continuous loss reduction due to factors such as the impact of centralized procurement, cost reduction measures, and a focus on core business, with net profit forecasts for 2025 and 2026 adjusted to -30 million and -96 million USD respectively, and a new forecast for 2027 set at 133 million USD [1] Group 1: Company Announcements - The company recently announced that it will terminate the consolidation of MicroPort Brain Science due to its inability to control it, while still maintaining significant influence [2] - MicroPort Heart Communication held a shareholders' meeting to approve a major asset restructuring proposal for the acquisition of MicroPort Rhythm Management, which will enhance the integration of its structural heart disease and rhythm management core business segments [2] Group 2: Governance and Growth - The governance structure has improved with the strategic investment from a fund under Shanghai Shenda Capital, which is expected to inject new momentum into governance and business development [3] - The recent restructuring of the rhythm management and structural heart disease business aims to create a comprehensive heart disease platform, integrating AI diagnostic and algorithm technology with existing treatment technologies [3] - The company is actively building a global commercialization platform to support the international expansion of its products, with overseas revenue reaching 59.8 million USD in the first half of 2025, a year-on-year increase of 57.3% [3] Group 3: Financial Performance - The company has significantly improved its profitability through a focus on core business and resource optimization, with a revenue of 548 million USD in the first half of 2025, a year-on-year decrease of 2.0% [4] - The net loss narrowed significantly from 107 million USD in the same period last year to 36.36 million USD, indicating a turning point in operations [4] - The improvement in profitability is attributed to effective cost control, with operational expense ratio optimized by 8.1 percentage points and R&D expense ratio reduced from 20.6% to 13.2% [4] - The company has set performance targets to limit net losses to no more than 110 million USD in the first half of 2025 and no more than 55 million USD for the entire year, with a target of achieving net profits of at least 45 million USD in the first half of 2026 and at least 90 million USD for the full year [4]

公司研究 心律管理业务重组合并，母公司亏损如期收窄中 2025 年 12 月 31 日 ——微创医疗（0853.HK）跟踪点评 要点 事件：公司近期公告 1）根据微创医疗集团会计政策其无法控制微创脑科学但仍 对其保持重大影响力，故终止合并微创脑科学，构成须予披露交易。2）微创心 通召开股东大会，审议通过并购微创心律管理有限公司的重大资产重组议案。此 次并购将推动微创医疗旗下结构性心脏病与心律管理两大核心业务板块的深度 整合。 点评： 治理结构改善注入新动能，出海业务成为核心增长引擎。公司治理层面，上实资 本旗下基金成为公司重要战略股东，有望在治理和业务发展方面注入新动能。公 司近期完成心律管理与结构性心脏病业务的重组，旨在打造综合心脏病平台，新 公司将融合微创心律管理的 AI 诊断及算法技术，与微创心通在结构性心脏病介 入治疗、输送系统及生物材料方面的技术积累，打造"结构性心脏病+心律管理 +心衰管理"一体化平台。公司亦公告终止合并微创脑科学，我们认为治理改善 持续推进中。同时，公司积极搭建全球通商业化平台，助力各业务板块产品出海， 25H1 出海业务收入已达 5,980 万美元，同比增长 57.3%，有效对 ...